{"createdAt":"8/2/2020, 2:35:28 PM","timestamp":1596393328094,"Company ID number":"630","DMX_ISSUER_NAME":"Joincare Pharmaceutical Group Industry Co.,Ltd.","DMX_ISSUER_ID":"IID000000002171988","Country of Classification":"CHINA","name":"Joincare Pharmaceutical Group Industry Co Ltd ","code":"600380","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"健康元药业集团股份有限公司_朱保国","group":"board","name":"朱保国","title":"董事长,董事","isMale":true,"age":"58","degree":"本科","salary":"310.6万","stockAmount":"-","description":"朱保国先生,58岁,现为丽珠医药集团股份有限公司董事长、非执行董事及战略委员会主席,并于本集团其他附属公司兼任董事。1985年毕业于河南师范大学化学系并获学士学位。自2002年起至今一直任丽珠医药集团股份有限公司董事长,2006年4月至2013年9月期间曾兼任丽珠医药集团股份有限公司总裁。朱保国先生为健康元创始人,现任该公司董事长。自2014年11月起担任深圳市工商联(总商会)荣誉副会长。朱保国先生为丽珠医药集团股份有限公司控股股东之一刘广霞女士的配偶。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_刘广霞","group":"board","name":"刘广霞","title":"副董事长,董事","isMale":false,"age":"51","degree":"本科","salary":"308.9万","stockAmount":"-","description":"刘广霞女士,现为丽珠医药集团股份有限公司副董事长及非执行董事。1990年于河南师范大学英语专业毕业。自1999年1月和1999年11起,分别任深圳市百业源投资有限公司及健康元副董事长,自2007年4月2008年6月起至今担任丽珠医药集团股份有限公司非执行董事和副董事长。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_邱庆丰","group":"board","name":"邱庆丰","title":"董事","isMale":true,"age":"49","degree":"硕士","salary":"274.0万","stockAmount":"35.74万","description":"邱庆丰先生,49岁,现为丽珠医药集团股份有限公司非执行董事。2007年9月取得中欧国际工商学院高级管理人员工商管理硕士学位。中国注册会计师非职业会员。1996年加入深圳太太药业有限公司,现任健康元董事及总裁。自2005年6月至2007年4月期间,曾担任丽珠医药集团股份有限公司监事及监事长,自2007年4月起至今任丽珠医药集团股份有限公司非执行董事。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_林楠棋","group":"board","name":"林楠棋","title":"董事","isMale":true,"age":"38","degree":"本科","salary":"138.0万","stockAmount":"49.1万","description":"林楠棋先生:男,1982年生,天津商学院生物工程本科,工学学士学位。曾任北大医药重庆大新药业股份有限公司车间主管,丽珠集团新北江制药股份有限公司车间经理、生产总监、副总经理,健康元药业集团股份有限公司全资子公司焦作健康元生物制品有限公司总经理,现任健康元药业集团股份有限公司副总裁及全资子公司深圳市海滨制药有限公司总经理。","lastUpdated":"2019-12-07"},{"id":"健康元药业集团股份有限公司_崔利国","group":"board","name":"崔利国","title":"独立董事","isMale":true,"age":"50","degree":"硕士","salary":"9.600万","stockAmount":"-","description":"崔利国先生,1970年生,法学硕士,北京观韬中茂律师事务所(曾用名“观韬律师事务所”)创始合伙人及管理委员会主任,现任健康元药业集团股份有限公司独立董事,兼任亚太卫星控股有限公司(证券代码:01045)、中核国际有限公司(证券代码:02302)、中国软件与技术服务股份有限公司(证券代码:600536)、安信证券股份有限公司及北京人寿保险股份有限公司独立董事。崔利国于二零二零年六月二十三日获委任为先丰服务集团有限公司独立非执行董事。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_覃业志","group":"board","name":"覃业志","title":"独立董事","isMale":true,"age":"46","degree":"本科","salary":"--","stockAmount":"-","description":"覃业志先生:男,1974年生,大学本科毕业,中国注册会计师执业会员、中国注册税务师执业会员、中国注册资产评估师非执业会员。历任深圳市正风利富会计师事务所审计员、深圳市金正会计师事务所合伙人、亚太(集团)会计师事务所(特殊普通合伙)合伙人,2014年起至今任立信会计师事务所(特殊普通合伙)合伙人。","lastUpdated":"2020-05-30"},{"id":"健康元药业集团股份有限公司_霍静","group":"board","name":"霍静","title":"独立董事","isMale":false,"age":"44","degree":"本科","salary":"6.140万","stockAmount":"-","description":"霍静女士:女,1976年生,大学本科毕业。中华全国律师协会会员,腾讯大粤房产智库成员,中国法院网、中顾网、华律网、南方都市报、深圳晚报等特邀律师。2007年起至今任广东国晖律师事务所律师、合伙人。曾任多届深圳市律师协会房地产专业委员会委员,先后担任深圳市蓝科迅通科技有限公司、深圳市世纪弘博商贸有限公司、安徽长朗三维科技有限公司、深圳市智微智能科技开发有限公司、深圳市科锐尔自动化设备有限公司、卡尔丹顿服饰股份有限公司等多家公司法律顾问,全面负责企业法律事务的审核,经济合同的起草及修订并出具法律意见书等。","lastUpdated":"2019-05-11"},{"id":"健康元药业集团股份有限公司_余孝云","group":"supervisoryCommittee","name":"余孝云","title":"监事会主席","isMale":true,"age":"52","degree":"硕士","salary":"40.73万","stockAmount":"-","description":"余孝云先生,1968年生,大学本科毕业,澳洲格林威治大学工商管理硕士。曾于河南中医药研究院工作,1992年12月至今于健康元药业集团股份有限公司历任技术部经理、中药研究所政府事务经理、研究所副所长,现为健康元药业集团股份有限公司研究所副所长。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_彭金花","group":"supervisoryCommittee","name":"彭金花","title":"监事","isMale":false,"age":"58","degree":"大专","salary":"83.43万","stockAmount":"3.804万","description":"彭金花:女,1962年生,大学专科毕业。曾任核工业部国营二七二厂资料员及其职工医院会计、衡阳市广播电视大学教师、深圳市新时代工业城实业有限公司财务经理,于1994年3月进入健康元药业集团股份有限公司历任财务主管、计财部经理、财务部经理,现任健康元药业集团股份有限公司总裁助理。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_谢友国","group":"supervisoryCommittee","name":"谢友国","title":"监事","isMale":true,"age":"63","degree":"本科","salary":"43.26万","stockAmount":"7.544万","description":"谢友国:男,1957年生,化学制药大学本科,于2003年历任健康元药业集团股份有限公司全资子公司深圳太太药业有限公司药厂总监,健康元药业集团股份有限公司全资子公司深圳市海滨制药有限公司常务副总经理,总经理,现任深圳市海滨制药有限公司巡视员。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_邱庆丰","group":"manager","name":"邱庆丰","title":"总裁","isMale":true,"age":"49","degree":"硕士","salary":"274.0万","stockAmount":"35.74万","description":"邱庆丰先生,49岁,现为丽珠医药集团股份有限公司非执行董事。2007年9月取得中欧国际工商学院高级管理人员工商管理硕士学位。中国注册会计师非职业会员。1996年加入深圳太太药业有限公司,现任健康元董事及总裁。自2005年6月至2007年4月期间,曾担任丽珠医药集团股份有限公司监事及监事长,自2007年4月起至今任丽珠医药集团股份有限公司非执行董事。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_赵凤光","group":"manager","name":"赵凤光","title":"董事会秘书,副总裁","isMale":true,"age":"45","degree":"硕士","salary":"138.6万","stockAmount":"16.74万","description":"赵凤光先生,1975年生,经济学学士学位,理学硕士学位,具助理研究员资格,曾任沈阳药科大学校长秘书、深圳中药及天然药物研究中心理事会秘书兼办公室主任、深圳清华大学研究院中药实验室主任助理;于2011年8月份起历任健康元药业集团股份有限公司研究所项目调研与管理部经理,集团研究所副所长兼项目调研总监,控股子公司上海方予董事,现任健康元药业集团股份有限公司副总裁兼董事会秘书。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_林楠棋","group":"manager","name":"林楠棋","title":"副总裁","isMale":true,"age":"38","degree":"本科","salary":"138.0万","stockAmount":"49.1万","description":"林楠棋先生:男,1982年生,天津商学院生物工程本科,工学学士学位。曾任北大医药重庆大新药业股份有限公司车间主管,丽珠集团新北江制药股份有限公司车间经理、生产总监、副总经理,健康元药业集团股份有限公司全资子公司焦作健康元生物制品有限公司总经理,现任健康元药业集团股份有限公司副总裁及全资子公司深圳市海滨制药有限公司总经理。","lastUpdated":"2019-12-07"},{"id":"健康元药业集团股份有限公司_俞雄","group":"manager","name":"俞雄","title":"副总裁","isMale":true,"age":"59","degree":"本科","salary":"171.3万","stockAmount":"11万","description":"俞雄先生,59岁,研究员,复旦大学理学学士学位。曾任上海医药工业研究院化学部主任、副院长;中国医药工业研究总院副院长;历任上海现代制药股份有限公司(600420.SH)董事以及山东鲁抗医药股份有限公司(600789.SH)、广东太安堂药业股份有限公司(002433.SZ)、丽珠医药集团股份有限公司及山东新华制药股份有限公司(000756.SZ)独立董事;曾任国药集团扬州威克生物工程有限公司总经理、董事长;曾兼任上海交通大学、华东理工大学、华东师范大学客座教授。自2016年10月及2018年11月起至今,分别任健康元副总裁及健康元控股子公司上海方予健康医药科技有限公司董事长。自2016年12月起至今,任天津天药药业股份有限公司(600488.SH)独立董事。自2019年9月起至今,任四川百利天恒药业股份有限公司独立董事。兼任中国药学会常务理事、制药工程专业委员会名誉主任委员,上海市化学化工学会荣誉理事。","lastUpdated":"2018-08-28"},{"id":"健康元药业集团股份有限公司_汤凌志","group":"manager","name":"汤凌志","title":"财务负责人","isMale":true,"age":"44","degree":"大专","salary":"84.83万","stockAmount":"9.672万","description":"汤凌志先生,男,1976年生,中国国籍,大学专科学历,中级会计师。曾于湖南省再生资源公司工作,1999年4月加入健康元药业集团股份有限公司,历任健康元药业集团股份有限公司销售会计、财务主管、子公司财务总监,现任健康元药业集团股份有限公司财务总监。","lastUpdated":"2019-09-24"}],"companyName":"健康元药业集团股份有限公司","province":"广东省","englishName":"Joincare Pharmaceutical Group Ind. Co.","industry":"医药生物 — 化学制药","website":"www.joincare.com","mainBusiness":"生产经营中成药、口服液、片剂、胶囊剂、颗粒剂、激素类片剂、保健食品、化妆品等。","productsName":["参芪扶正注射液","注射用美罗培南","注射用尿促卵泡素","注射用醋酸亮丙瑞林微球","艾普拉唑肠溶片","鼠神经生长因子"],"actualController":"朱保国","actualControllerSharePercentage":"41.63%","registeredCapital":"19.48亿元","employeeAmount":"12699","phone":"86-0755-86252656;86-0755-86252388","location":"广东省深圳市南山区高新区北区郎山路17号健康元药业集团大厦","chineseDescription":"健康元药业集团股份有限公司是一家专注于医药及保健品生产销售的公司.公司的主要产品有中成药、口服液、片剂、胶囊剂、颗粒剂、激素类片剂等。公司成立二十多年来,一直专注于医药、保健品领域的经营,其优良的产品质量及市场服务等树立了公司长久以来成功的品牌形象,并为公司赢得了广泛的市场认可。公司保健品“太太”、“静心”、“鹰牌”,处方药“倍能”、“速能”及丽珠集团旗下系列产品的众多品牌,为公司赢得了广泛知名度和品牌优势。","foundedDate":"1992-12-18","goPublicDate":"2001-06-08","companyHistory":"本公司的前身为“深圳爱迷尔食品有限公司”，是经深圳市工商行政管理局核准，于一九九二年十二月十八日正式设立的中外合资经营企业，主要从事太太口服液的生产和销售。\n　　一九九四年一月十九日，本公司更名为“深圳太太保健食品有限公司”。一九九五年七月四日，本公司又更名为“深圳太太药业有限公司”。\n　　一九九九年九月十六日和十一月十日，经本公司股东会决议和深圳市人民政府深府(1999)197号文批准，本公司以一九九九年八月三十一日为股份制改组基准日，整体改组为股份有限公司。\n　　本公司于一九九九年十一月十二日召开创立大会，并于一九九九年十一月二十四日办理了工商变更登记手续，换领了注册号为企合粤深总字第103358A的企业法人营业执照，并更名为“深圳太太药业股份有限公司”。本公司将会计上的股份制改组生效日确定为一九九九年九月一日。\n　　二零零一年二月六日，中国证券监督管理委员会以证监发行字[2001]21号文《关于核准深圳太太药业股份有限公司公开发行股票的通知》，同意本公司向社会公众发行境内上市内资股(A股)股票。二零零一年六月八日，本公司股票在上海证券交易所上市交易。\n　　二零零一年五月二十五日，本公司办理了工商变更登记手续，换领了注册号为4403011066279的企业法人营业执照。\n　　二零零二年五月二十一日，本公司股东大会通过决议，以二零零一年十二月三十一日股本为基数，以资本公积每10股转增5股股本。本公司已换领了新的企业法人营业执照，注册号不变。\n　　二零零三年六月四日，本公司更名为“深圳健康药业集团股份有限公司”。同年九月二十九日，本公司更名为“健康元药业集团股份有限公司”。\n　　二零零三年九月二十九日，本公司股东大会通过决议，以二零零三年六月三十日股本为基数，以资本公积每10股转增5股股本。本公司已换领了新的企业法人营业执照，注册号不变。\n　　二零零五年十二月二日，经中华人民共和国商务部批准，本公司变更为外商投资股份有限公司(外资比例低于25%)，并已换领了新的企业法人营业执照，注册号变更为企合粤深总字第111262号。\n　　二零零六年十月十六日，本公司股东大会通过本公司股权分置改革方案，并于二零零六年十一月二十三日实施。根据该方案，流通股股东每持有10股流通股获得非流通股股东执行的3.80股股份对价。实施股权分置改革方案后，本公司股东的持股数量和持股比例发生变动，但本公司总股本、资产、负债、所有者权益和净利润等财务指标均不因股权分置改革方案的实施而发生变化。\n　　二零零八年三月二十六日，本公司股东大会通过决议，以本公司二零零七年末总股本609,930,000股为基数，向全体股东每10股送8股并派发现金股利1元(含税)。本公司已换领了新的企业法人营业执照，注册号不变。\n　　二零一零年三月三十一日，本公司股东大会通过决议，以二零零九年十二月三十一日股本为基数，以资本公积每10股转增2股股本。本公司已换领了新的企业法人营业执照，注册号不变。\n　　二零一一年二月一十五日，本公司股东大会通过决议，同意本公司在回购资金总额不超过3亿元人民币及回购股份价格不超过12.00元人民币/股的条件下，通过上海证券交易所交易系统以集中竞价交易方式回购公司部分社会公众股并依法注销，回购期限为：自股东大会通过之日起12个月。截至2011年11月30日止，公司回购股份29,252,223股，占公司已发行总股本的比例约为2.220%，回购的最高价为人民币11.33元/股，最低价为人民币7.07元/股，支付总金额为人民币299,999,708.87元(含印花税、佣金)，已达到3亿元人民币上限，回购部分社会公众股份方案实施完毕，并已在中国证券登记结算有限责任公司上海分公司办理所回购股份的注销手续。回购后股本为1,288,196,577股。\n　　二零一二年四月二十日，本公司股东大会通过决议，以公司股本1,288,196,577股为基数，以资本公积每10股转增2股股本，转增后股本为1,545,835,892股。本公司已换领新的企业法人营业执照，注册号为440301501126176。\n　　二零一五年五月本公司实施股权激励计划，对214名股权激励对象发行38,043,400份限制性股票，注册资本变更为1,583,879,292元，二零一五年七月在中国证券登记结算有限责任公司上海分公司完成证券变更登记。并于二零一六年二月二十三日办理了工商变更登记，统一社会信用代码：91440300618874367T。\n　　二零一五年十二月二十一日，本公司将二零一五年五月股权激励计划的首批预留限制性股票授予39名股权激励对象，实际行权数量为3,150,000股，行权后注册资本变更为1,587,029,292股，二零一六年二月在中国证券登记结算有限责任公司上海分公司完成证券变更登记。\n　　二零一六年五月十六日，本公司将二零一五年五月股权激励计划的第二批预留限制性股票授予38名股权激励对象，实际行权数量为1,360,000股，行权后注册资本变更为1,588,389,292股，二零一六年七月二十五日在中国证券登记结算有限责任公司上海分公司完成证券变更登记。\n　　二零一六年八月十八日，本公司根据第六届董事会第二十次会议审议通过了《关于回购注销部分激励对象已获授但尚未解锁的限制性股票的议案》，本次回购股份1,250,000股，回购后注册资本变更为1,587,139,292股，二零一六年十一月十八日在中国证券登记结算有限责任公司上海分公司完成证券变更登记。\n　　本公司控股股东为深圳市百业源投资有限公司，最终实际控制人为朱保国。\n　　二零一七年四月二十七日，本公司第六届董事会第三十三次会议审议通过了《关于回购注销部分激励对象已获授但尚未解锁的限制性股票的议案》，本次回购股份12,123,020股，回购后的股本为人民币1,573,778,272元，二零一七年七月十九日在中国证券登记结算有限责任公司上海分公司完成证券变更登记。\n　　二零一八年三月二十一日，本公司第六届董事会第四十六次会议审议通过了《关于回购注销部分激励对象已获授但尚未解锁的限制性股票的议案》，本次回购股份850,000股，回购后的股本为人民币1,572,928,272元，二零一八年六月十九日在中国证券登记结算有限责任公司上海分公司完成证券变更登记。\n　　二零一八年十月十八日，根据公司二零一七年五月十一日召开的六届董事会三十四次会议和二零一七年六月八日召开的2016年年度股东大会决议、二零一七年十一月十六日召开的六届董事会四十一次会议决议、二零一八年四月二十六日召开的六届董事会四十八次会议和二零一八年五月二十二日召开的2017年年度股东大会决议，并于二零一八年八月十七日经中国证券监督管理委员会以证监许可[2018]1284号文《关于核准健康元药业集团股份有限公司配股的批复》核准，公司向原股东配股发行人民币普通股（A股）365,105,066股，每股面值人民币1.00元，发行后公司股本变更为1,938,033,338元。此次增资已由瑞华会计师事务所出具瑞华验字[2018]40060006号验资报告验证确认。收起▲","shareholders":[],"englishDescription":"Joincare Pharmaceutical Group Industry Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals and healthcare products. The Company's products include chemical materials and intermediates, chemical agents, health products, traditional Chinese medicines, diagnostic reagents and equipment. The Company is also engaged in electricity business. The Company distributes its products within domestic market and to overseas markets. ","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"44.39","Price to sales (ttm)":"3.27","Price to book (mrq)":"3.62","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"10.28","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"16.33","Return on equity (ttm)":"7.68","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"12,497.69","Cash payments":"(3,313.87)","Cash taxes paid":"(1,281.89)","Changes in working capital":"(5,589.49)","Cash from operating activities":"2,312.45","Capital expenditures":"(703.20)","Other investing cash flow items, total":"2,013.66","Cash from investing activities":"1,310.46","Financing cash flow items":"(643.97)","Total cash dividends paid":"(375.37)","Issuance (retirement) of debt, net":"(1,040.68)","Cash from financing activities":"(2,060.02)","Foreign exchange effects":"17.22","Net change in cash":"1,580.11"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"19.87","52 Week High":"22.47","52 Week Low":"7.84","Pricing date":"","10 Day Average Trading Volume":"53.19","Market Capitalization":"38,685.31","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"703.49","Beta":"1.58","1 Day Price Change":"0.30","13 Week Price Return (Daily)":"58.58","26 Week Price Return (Daily)":"91.43","5 Day Price Return (Daily)":"2.37","52 Week Price Return (Daily)":"135.43","Year To Date Price Return (Daily)":"91.98","Month to Date Price Return (Daily)":"22.35","Price Relative to S&P500 (4 Week)":"23.22","Price Relative to S&P500 (13 Week)":"37.02","Price Relative to S&P500 (26 Week)":"72.14","Price Relative to S&P500 (52 Week)":"106.89","Price Relative to S&P500 (YTD)":"76.91"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.46","EPS excl. Extra Items (TTM)":"0.45","EPS Normalized (Annual)":"0.48","Revenue per Share (Annual)":"6.18","Revenue per Share (TTM)":"6.09","Book Value (Per Share Annual)":"5.34","Book Value (Per Share Quarterly)":"5.48","Tangible Book Value (Per Share Annual)":"4.67","Tangible Book Value (Per Share Quarterly)":"4.80","Cash Per Share (Per Share Annual)":"5.65","Cash Per Share (Per Share Quarterly)":"4.69","Cash Flow (Per Share Annual)":"1.23","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.16","Dividends (Per Share TTM)":"0.16","EBITD (Per Share TTM)":"1.05","EPS Basic excl. Extra Items (Annual)":"0.46","EPS Basic excl. Extra Items (TTM)":"0.45","EPS incl. Extra Items (Annual)":"0.46","EPS incl. Extra Items (TTM)":"0.45","Free Cash Flow (Per Share TTM)":"0.62","Dividend (Per Share 5Y)":"0.14"},"Valuation":{"P/E excl. Extra Items (Annual)":"43.06","P/E excl. Extra Items (TTM)":"44.39","P/E Normalized (Annual)":"41.01","Price to sales (Annual)":"3.23","Price to sales (TTM)":"3.27","Price to Tangible Book (Annual)":"4.27","Price to Tangible Book (Quarterly)":"4.15","Price to Free Cash Flow (Per Share Annual)":"31.35","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"32.27","Price to Book (Annual)":"3.72","Price to Book (Quarterly)":"3.62","P/E Basic excl. Extra Items (TTM)":"25.60","P/E excl. Extra Items High (TTM)":"52.50","P/E excl. Extra Items Low (TTM)":"7.32","P/E incl. Extra Items (TTM)":"44.39","Net Debt (Interim)":"-8,012.99","Net Debt (Annual)":"-7,534.35","Dividend Yield (5Y)":"1.48","Dividend Yield":"0.81","Current Dividend Yield (TTM)":"0.81"},"Financial Strength":{"Free Cash Flow (Annual)":"1,233.88","Current Ratio (Annual)":"2.25","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"34.67","Quick Ratio (Annual)":"2.04","Total Debt/Total Equity (Annual)":"33.03","Current EV/Free Cash Flow (Annual)":"29.38","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"2.86","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"2.55","Total Debt/Total Equity (Quarterly)":"10.28","Free Cash Flow (TTM)":"1,198.75","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"35.69"},"Margins":{"Gross Margin (Annual)":"64.35","Gross Margin (TTM)":"62.72","Net Profit Margin % (Annual)":"15.44","Net Profit Margin (TTM)":"15.52","Operating Margin (Annual)":"18.31","Operating Margin (TTM)":"18.90","Pretax Margin (TTM)":"18.27","Pretax Margin (Annual)":"18.18","Operating Margin (5Y)":"22.11","Pretax Margin (5Y)":"22.96","Free Operating Cash Flow/Revenue (5Y)":"7.93","Free Operating Cash Flow/Revenue (TTM)":"10.14","Gross Margin (5Y)":"62.56","Net Profit Margin (5Y)":"18.69"},"Management Effectiveness":{"Return on Assets (Annual)":"7.34","Return on Equity (TTM)":"7.68","Return on Average Equity (Annual)":"8.94","Return on Average equity (TTM)":"8.38","Return on Investment (Annual)":"17.02","Return on Investment (TTM)":"16.33","Return on Average Assets (5Y)":"10.20","Return on Average Equity (5Y)":"13.32","Return on Investment (5Y)":"23.37","Asset Turnover (Annual)":"0.48","Asset Turnover (TTM)":"0.49","Inventory Turnover (Annual)":"2.91","Inventory Turnover (TTM)":"3.02","Net Income/Employee (Annual)":"158,984.10","Net Income/Employee (TTM)":"144,559.10","Receivables Turnover (Annual)":"6.18","Receivables Turnover (TTM)":"3.93","Revenue/Employee (Annual)":"1,029,532.00","Revenue/Employee (TTM)":"931,216.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-4.63","Revenue Growth Rate (5Y)":"10.06","EPS Growth (Quarterly YoY)":"-8.81","EPS Growth (TTM YoY)":"4.51","EPS Growth Rate (5Y)":"17.28","Dividend Growth Rate (3Y)":"3.29","Revenue Growth (TTM YoY)":"2.51","Revenue Growth (Per Share 5Y)":"7.26","Revenue Growth Rate (3Y)":"7.21","EPS Growth Rate (3Y)":"21.37","Book Value Growth Rate (Per Share 5Y)":"15.90","Tangible Book Value Total Equity CAGR (5Y)":"22.67","Capital Spending growth rate 5 year":"-2.95","EBITDA CAGR (5Y)":"14.70","EBITDA Interim CAGR (5Y)":"16.50","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"0.55","Net Profit Margin Growth Rate (5Y)":"10.87"},"Income Statement":{"Revenue (Annual)":"11,980.15","Revenue (TTM)":"11,825.51","EBITD (Annual)":"2,543.64","EBITD (TTM)":"2,032.18","Earnings Before Taxes (Annual)":"2,178.10","Earnings Before Taxes (TTM)":"2,160.24","Net Income to Common (Annual)":"894.35","Net Income to Common (TTM)":"868.72","Earnings Before Taxes Normalized (Annual)":"2,230.73","Net Income Available to Common Normalized (Annual)":"939.05","Diluted Normalized EPS excl. Extra Items (TTM)":"0.47"}}}